Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALKS NASDAQ:CLDX NASDAQ:HALO NASDAQ:RGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKSAlkermes$36.80$33.55$25.17▼$39.56$6.13B0.312.15 million shs907,753 shsCLDXCelldex Therapeutics$30.73$32.01$18.55▼$35.79$2.41B0.98724,510 shs582,927 shsHALOHalozyme Therapeutics$68.32$65.84$51.06▼$82.22$8.10B0.891.78 million shs1.20 million shsRGENRepligen$115.06$117.76$100.99▼$175.77$6.49B1.091.40 million shs722,882 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKSAlkermes0.00%-1.81%+10.48%+14.32%+25.38%CLDXCelldex Therapeutics0.00%-1.95%-7.69%+26.36%+51.01%HALOHalozyme Therapeutics0.00%+1.79%+4.53%-3.28%+25.27%RGENRepligen0.00%+11.85%-2.16%-15.02%-2.62%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKSAlkermes$36.80$33.55$25.17▼$39.56$6.13B0.312.15 million shs907,753 shsCLDXCelldex Therapeutics$30.73$32.01$18.55▼$35.79$2.41B0.98724,510 shs582,927 shsHALOHalozyme Therapeutics$68.32$65.84$51.06▼$82.22$8.10B0.891.78 million shs1.20 million shsRGENRepligen$115.06$117.76$100.99▼$175.77$6.49B1.091.40 million shs722,882 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKSAlkermes0.00%-1.81%+10.48%+14.32%+25.38%CLDXCelldex Therapeutics0.00%-1.95%-7.69%+26.36%+51.01%HALOHalozyme Therapeutics0.00%+1.79%+4.53%-3.28%+25.27%RGENRepligen0.00%+11.85%-2.16%-15.02%-2.62%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALKSAlkermes 2.76Moderate Buy$45.4023.37% UpsideCLDXCelldex Therapeutics 2.80Moderate Buy$49.7861.98% UpsideHALOHalozyme Therapeutics 2.50Moderate Buy$80.6718.07% UpsideRGENRepligen 2.87Moderate Buy$166.1544.41% UpsideCurrent Analyst Ratings BreakdownLatest CLDX, HALO, ALKS, and RGEN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2026RGENRepligen Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$160.005/14/2026RGENRepligen Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeModerate Buy5/13/2026ALKSAlkermes Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$45.00 ➝ $48.005/13/2026CLDXCelldex Therapeutics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$38.00 ➝ $54.005/12/2026HALOHalozyme Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C) ➝ Buy (B-)5/12/2026HALOHalozyme Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$96.00 ➝ $93.005/11/2026ALKSAlkermes Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C+) ➝ Hold (C)5/8/2026CLDXCelldex Therapeutics BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$45.00 ➝ $48.005/7/2026RGENRepligen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)5/6/2026ALKSAlkermes UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$42.00 ➝ $48.005/6/2026RGENRepligen BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$145.00 ➝ $160.00(Data available from 5/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALKSAlkermes$1.48B4.16$1.67 per share21.98$10.51 per share3.50CLDXCelldex Therapeutics$1.54M1,566.23N/AN/A$5.81 per share5.29HALOHalozyme Therapeutics$1.40B5.80$4.77 per share14.32$1.85 per share36.93RGENRepligen$738.26M8.79$3.42 per share33.67$37.33 per share3.08Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALKSAlkermes$241.66M$0.9040.8966.91N/A9.78%9.26%5.66%7/28/2026 (Estimated)CLDXCelldex Therapeutics-$258.76M-$4.26N/AN/AN/AN/A-50.72%-46.59%8/6/2026 (Estimated)HALOHalozyme Therapeutics$316.89M$2.7824.587.430.2823.13%187.91%21.92%8/4/2026 (Estimated)RGENRepligen$48.89M$0.90127.8547.162.226.73%4.88%3.48%8/4/2026 (Estimated)Latest CLDX, HALO, ALKS, and RGEN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026HALOHalozyme Therapeutics$1.54$1.60+$0.06$1.22$358.60 million$376.71 million5/7/2026Q1 2026CLDXCelldex Therapeutics-$1.1472-$1.18-$0.0328-$1.18$0.80 million$0.02 million5/5/2026Q1 2026RGENRepligen$0.38$0.48+$0.10$0.15$192.05 million$194.26 million2/26/2026Q4 2025ALKSAlkermes$0.43$0.29-$0.14$0.29$380.44 million$384.55 million2/25/2026Q4 2025CLDXCelldex Therapeutics-$1.00-$1.22-$0.22-$1.22$1.53 million$0.12 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALKSAlkermesN/AN/AN/AN/AN/ACLDXCelldex TherapeuticsN/AN/AN/AN/AN/AHALOHalozyme TherapeuticsN/AN/AN/AN/AN/ARGENRepligenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALKSAlkermes0.852.271.70CLDXCelldex TherapeuticsN/A8.928.92HALOHalozyme Therapeutics8.812.762.33RGENRepligen0.269.207.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALKSAlkermes95.21%CLDXCelldex TherapeuticsN/AHALOHalozyme Therapeutics97.79%RGENRepligen97.64%Insider OwnershipCompanyInsider OwnershipALKSAlkermes4.59%CLDXCelldex Therapeutics5.20%HALOHalozyme Therapeutics2.50%RGENRepligen0.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALKSAlkermes2,050166.68 million159.03 millionOptionableCLDXCelldex Therapeutics15078.49 million74.41 millionOptionableHALOHalozyme Therapeutics390118.61 million115.65 millionOptionableRGENRepligen2,00056.41 million56.07 millionOptionableCLDX, HALO, ALKS, and RGEN HeadlinesRecent News About These CompaniesRepligen Corporation to Present at William Blair 46th Annual Growth Stock ConferenceMay 22 at 7:30 AM | globenewswire.comRepligen Announces Publication of the Company’s 2025 Corporate Sustainability ReportMay 20, 2026 | markets.businessinsider.comRepligen Announces Publication of the Company's 2025 Corporate Sustainability ReportMay 20, 2026 | globenewswire.comRepligen shares jump 4.1% as investors buy the dip after a sharp selloff; prior guidance update and short-covering may be factorsMay 19, 2026 | quiverquant.comQQ1 rundown: Repligen (NASDAQ:RGEN) vs other drug development inputs & services stocksMay 19, 2026 | msn.comRepligen, AdaptHealth, and IQVIA Stocks Trade Down, What You Need To KnowMay 17, 2026 | finance.yahoo.com1 growth stock with explosive upside and 2 facing headwindsMay 15, 2026 | msn.com5 Revealing Analyst Questions From Repligen’s Q1 Earnings CallMay 15, 2026 | finance.yahoo.comRepligen Shareholders Approve Directors, Auditor and Pay PlanMay 15, 2026 | tipranks.comRepligen Corporation (RGEN) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 12, 2026 | seekingalpha.comBarclays Maintains an “Overweight Rating” on Repligen Corporation (RGEN)May 11, 2026 | insidermonkey.comSwedbank AB Invests $4.15 Million in Repligen Corporation $RGENMay 10, 2026 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Repligen (RGEN) and IQVIA Holdings (IQV)May 7, 2026 | theglobeandmail.comRepligen Corporation to Present at Bank of America Securities 2026 Global Healthcare ConferenceMay 7, 2026 | globenewswire.comJPMorgan Chase & Co. Lowers Repligen (NASDAQ:RGEN) Price Target to $165.00May 6, 2026 | marketbeat.comRepligen's Q1 Earnings & Revenues Beat Estimates, Stock RisesMay 6, 2026 | zacks.comRepligen Corporation $RGEN Stock Position Decreased by UBS Group AGMay 6, 2026 | marketbeat.comRepligen forecasts $1.97-$2.05 EPS on $803M-$833M 2026 revenue, as it targets 1 point margin lift by end of 2027May 6, 2026 | seekingalpha.comRepligen Reshapes Operations And China Reach As Valuation Signals UpsideMay 6, 2026 | finance.yahoo.comRepligen: Q1 Earnings SnapshotMay 5, 2026 | stamfordadvocate.comSRepligen (RGEN) Q1 2026 Earnings Call TranscriptMay 5, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 2026Alphabet’s Earnings Didn’t Just Beat—They Changed the StoryBy Ryan Hasson | April 30, 2026As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants InBy Leo Miller | May 17, 2026CLDX, HALO, ALKS, and RGEN Company DescriptionsAlkermes NASDAQ:ALKS$36.80 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$36.79 -0.01 (-0.03%) As of 05/22/2026 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.Celldex Therapeutics NASDAQ:CLDX$30.73 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$30.45 -0.28 (-0.90%) As of 05/22/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.Halozyme Therapeutics NASDAQ:HALO$68.32 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$68.64 +0.32 (+0.47%) As of 05/22/2026 06:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.Repligen NASDAQ:RGEN$115.06 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$115.05 -0.01 (-0.01%) As of 05/22/2026 04:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Ross Stores Earnings Beat Sends Stock To New Highs Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins Apparel Earnings Winners and Losers: Ralph Lauren Takes Off SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? The Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May Appear Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
